73 4 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | PART TWO Results From June 2014 to June 2018, a total of 230 patients were randomly selected to receive antiemetic study treatment (Figure 1). Figure 1. Trial profile. 230 patients were enrolled and randomly assigned 77 assigned to DEX arma 79 assigned to MCP armb 75 assigned to PAL armc 13 did not complete study assessments: ▪ 5 due to noncompliance ▪ 4 due to sideeffects chemotherapy ▪ 4 unknown 17 did not complete study assessments: ▪ 8 due to noncompliance ▪ 5 due to sideeffects chemotherapy ▪ 4 unknown 12 did not complete study assessments: ▪ 4 due to noncompliance ▪ 5 due to sideeffects chemotherapy ▪ 3 unknown 60 were assessed for TC in the delayed period 66 were assessed for TC in the delayed period 63 were assessed for TC in the delayed period 247 patients were assessed for eligibility 17 were excluded before randomization; did not meet inclusion criteria Abbreviations: DEX, 3-day dexamethasone; MCP, metoclopramide; PAL, palonosetron; TC, total control
RkJQdWJsaXNoZXIy MjY0ODMw